These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11139533)

  • 1. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome.
    Falsetti L; Gambera A; Tisi G
    Hum Reprod; 2001 Jan; 16(1):36-42. PubMed ID: 11139533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L; Galbignani E
    Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism.
    Karrer-Voegeli S; Rey F; Reymond MJ; Meuwly JY; Gaillard RC; Gomez F
    Medicine (Baltimore); 2009 Jan; 88(1):32-45. PubMed ID: 19352298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms.
    Acién P; Mauri M; Gutierrez M
    Hum Reprod; 1997 Mar; 12(3):423-9. PubMed ID: 9130733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
    Frölich M; Lachinsky N; Moolenaar AJ
    Acta Endocrinol (Copenh); 1977 Feb; 84(2):333-42. PubMed ID: 138326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
    Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Balint-Perić L; Puzigaća Z
    Gynecol Endocrinol; 1989 Dec; 3(4):269-80. PubMed ID: 2516704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.
    Ruan X; Kubba A; Aguilar A; Mueck AO
    Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):183-190. PubMed ID: 28463030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy.
    Franks S; Layton A; Glasier A
    Hum Reprod; 2008 Feb; 23(2):231-2. PubMed ID: 18083746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasound study of ovarian and uterine morphology in women with polycystic ovary syndrome before, during and after treatment with cyproterone acetate and ethinyloestradiol.
    Venturoli S; Paradisi R; Saviotti E; Porcu E; Fabbri R; Orsini LF; Bovicelli L; Flamigni C
    Arch Gynecol; 1985; 237(1):1-10. PubMed ID: 2932064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.
    Bitzer J; Römer T; Lopes da Silva Filho A
    Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):172-182. PubMed ID: 28447864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
    Lemay A; Dodin S; Turcot L; Déchêne F; Forest JC
    Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences.
    Falsetti L; Gambera A; Andrico S; Sartori E
    Gynecol Endocrinol; 2002 Aug; 16(4):275-84. PubMed ID: 12396556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate.
    Eden JA
    Med J Aust; 1991 Nov; 155(10):677-80. PubMed ID: 1834923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
    Armstrong VL; Wiggam MI; Ennis CN; Sheridan B; Traub AI; Atkinson AB; Bell PM
    QJM; 2001 Jan; 94(1):31-7. PubMed ID: 11161134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of low dose flutamide plus Diane-35 in the treatment of idiopathic hirsutism and polycystic ovary syndrome.
    Boztosun A; Açmaz G; Ozturk A; Müderris II
    Ginekol Pol; 2013 Apr; 84(4):258-62. PubMed ID: 23700857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-androgenic steroid cyproterone acetate. Clinical pharmacology and therapeutic use in hirsutism and acne].
    van Wayjen RG; van den Ende A
    Ned Tijdschr Geneeskd; 1976 Jan; 120(5):189-95. PubMed ID: 129710
    [No Abstract]   [Full Text] [Related]  

  • 18. [Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome].
    Zhang J; Su M; Xu L; Yang Z; Yin W; Nie Y; Qiao X; Cheng R; Ma Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jul; 38(8):917-922. PubMed ID: 30187872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination.
    Kokaly W; McKenna TJ
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):379-82. PubMed ID: 10718837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease.
    Ciotta L; Cianci A; Giuffrida G; Marletta E; Aglianò A; Palumbo G
    Fertil Steril; 1996 Jan; 65(1):61-7. PubMed ID: 8557156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.